

Specimen Comments

Reasons for Request:

prev relapse responder to 8/52 of harvani march-may2016

Hepatitis C other tests

Hepatitis C other tests

HCV Resistance Analysis

NS5a resistance mutations: none detected

Other mutations (w.r.t. H77): R44K, T64A, R78K, K107T, R123Q, S131T, T135A, I144V, E171D, E181D

Susceptible to Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir and Velpatasvir

NS5b resistance mutations: None detected

Other mutations (w.r.t. H77): K98R, C110S, A117N, K124E, L184V, R300Q, Q309R, A327Q, S335G, N444D, R510K, G543C, R544Q, H566R

Susceptible to Dasabuvir and Sofosbuvir

Predicted subtype: 1a

Note: This is a developmental assay. No clinical decision should be made based only on the results of this test.

Results from this test represent the majority viral population in plasma at the time of sample. Drug susceptibilities are estimated solely on these genotypic results with no account taken of the prior drug treatment history. It is essential that results are not interpreted in isolation from clinical information.

This drug susceptibility interpretation is based on the geno2pheno (hcv) 0.92 web-based interpretation system (Max Planck Institut) and the GALEXOS (Simeprevir) Product Monograph.

These data will be stored in the Antiviral Unit and allied non-commercial databases.